Abbott Laboratories will use Compugen’s technology for the accelerated identification of drug targets across multiple therapeutic areas. Under the terms of the agreement, Abbott will license Compugen's LEADS computational biology platform.
The companies will jointly perform an integrated analysis of human genomic data, creating a comprehensive database that represents human mRNA molecules. Abbott will use the results, as well as further data provided by Compugen's Gencarta database, to identify and prioritize novel drug targets for the development of pharmaceutical and diagnostic products.
Abbott Laboratories is a global health care company involved in the discovery, development, manufacture and marketing of pharmaceuticals, nutritionals, and medical products, including devices and diagnostics. The company employs approximately 70,000 people and markets its products in more than 130 countries.
Israel’s Compugen merges computational technologies with biology, chemistry and medicine to enhance drug discovery and development. This capability is a proven basis for providing products and services to leading biotechnology and pharmaceutical companies and for in-house discovery. — (menareport.com)
© 2003 Mena Report (www.menareport.com)
